PAXLOVID 150 mg + 100 mg, film-coated tablet 30 tablets
Active ingredients: Nirmatrelvir, Ritonavir
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- PAXLOVID 150 mg + 100 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé et comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC de 30 (20 + 10) comprimés
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 2 May 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65579730CIP73024551CIP133400930245514Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| NIRMATRELVIRcomprimé de nirmatrelvir | 150 mg · un comprimé | SA |
| RITONAVIRcomprimé de ritonavir | 100 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.